Presented by

A Halley’s Comet-level event in the world of subscriptions is occurring at Microsoft: the company announced it will lower the price of its Game Pass Ultimate from $29.99 to $22.99. But with the price drop, Game Pass is also getting nerfed — new “Call of Duty” titles will no longer be added to the service at launch, instead joining the library about a year later during the following holiday season. 

The S&P 500, Russell 2000, and Nasdaq 100 closed lower on Tuesday. Stocks erased modest early gains and fell further on negative news reports about the status of peace talks between the US and Iran, which culminated in reports shortly before markets closed that Vice President Vance’s trip to Pakistan for those talks had been canceled. Postmarket, President Trump seemed to give the market some hope with a Truth Social post extending the ceasefire indefinitely.

Biotechs working on psychedelic-based treatments have long been a staple in retail investors’ portfolios. Now, several are poised to gain federal approval, potentially turning them from cash-burning to money-printing. 

Dan Ahrens, manager of the AdvisorShares Psychedelics ETF, said institutional money is starting to enter a space that has been historically dominated by retail investors. Large banks like Deutsche Bank and Morgan Stanley have initiated coverage of psychedelic biotechs, which are predominantly covered by boutique research firms. 

Companies developing psychedelic treatments face several hurdles, including the logistics of testing substances that are often considered dangerous drugs by the federal government, and at times an unfriendly FDA. 

The FDA has already approved a form of ketamine (which is technically not considered a psychedelic, though that’s a subject of debate) for treatment-resistant depression, called Spravato, which is a nasal spray sold by Johnson & Johnson. It’s expected to sell $2 billion worth this year. The active compound is esketamine, a component of the anesthetic and party drug ketamine. 

The companies that are participating in the technology-enabled economy aren’t limited to the tech sector or a single exchange. A traditional tech sector ETF may not include companies like the so-called “Magnificent 7”, and other companies with technology-related business activities due to sector classification frameworks

That’s why NYSX is designed to provide exposure beyond traditional sector classifications to give investors access to leading companies across today’s technology ecosystem.

The Global X NYSE^® 100 ETF (NYSX) seeks to track the NYSE^® 100 Index, a rules-based index of 100 companies shaping modern economy, including businesses with exposure to cloud computing, digital media, payments, e-commerce, and artificial intelligence.

Learn more about NYSX and its investing approach. 

Hedge funds are following retail traders into the stocks the masses never stopped buying.

Last August, Jain discussed how retail activity tended to “crowd in” institutional buyers in meme stocks, while Goldman’s John Marshall advised clients to piggyback on stocks beloved by retail traders. 

Speculative, retail-geared assets proceeded to go on a tremendous run that soured in October. But there are some early indications that a similar bout of speculative fervor is bubbling up once more.

During Tim Cook’s 15-year tenure as CEO, he oversaw Apple stock gains of 1,933%, nearly quadrupling the S&P 500’s return in that time. When John Ternus takes over the role, Wall Street has some big expectations — as well as recommendations — for what he needs to do to “define his own path and the future success of Apple.”